Carmustine
Bicnu, Carmustine, Gliadel (carmustine) is a small molecule pharmaceutical. Carmustine was first approved as Bicnu on 1982-01-01. It is used to treat brain neoplasms, carcinoma, colonic neoplasms, ependymoma, and glioblastoma amongst others in the USA. It has been approved in Europe to treat hodgkin disease and non-hodgkin lymphoma. The pharmaceutical is active against glutathione reductase, mitochondrial.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Bicnu, Carmustine, Gliadel (discontinued: Carmustine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carmustine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BICNU | Avet Lifesciences | N-017422 RX | 1982-01-01 | 1 products, RLD, RS |
| GLIADEL | Azurity | N-020637 RX | 1996-09-23 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| carmustine | NDA authorized generic | 2025-01-02 |
| gliadel | New Drug Application | 2024-12-05 |
Indications
FDA
EMA
Show 1 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9050 | Injection, carmustine, 100 mg |
Clinical
Clinical Trials
288 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 30 | 99 | 24 | 1 | 11 | 151 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 19 | 38 | 5 | 1 | 3 | 57 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 6 | 18 | 7 | 1 | 3 | 33 |
| B-cell lymphoma | D016393 | — | — | 10 | 16 | 4 | 1 | 3 | 31 |
| Burkitt lymphoma | D002051 | — | C83.7 | 2 | 2 | — | 1 | 2 | 6 |
| Waldenstrom macroglobulinemia | D008258 | HP_0005508 | C88.0 | — | 2 | — | 1 | 2 | 5 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 9 | 25 | 8 | — | 2 | 36 |
| Central nervous system neoplasms | D016543 | — | — | 16 | 18 | 4 | — | 1 | 35 |
| Nervous system neoplasms | D009423 | — | — | 16 | 17 | 4 | — | — | 33 |
| Glioma | D005910 | EFO_0000520 | — | 14 | 16 | 2 | — | 3 | 30 |
| Multiple myeloma | D009101 | — | C90.0 | 3 | 17 | 8 | — | 2 | 29 |
| Hodgkin disease | D006689 | — | C81 | 8 | 18 | 2 | — | 4 | 27 |
| Plasma cell neoplasms | D054219 | — | — | 2 | 16 | 8 | — | 1 | 26 |
| Leukemia | D007938 | — | C95 | 3 | 14 | 2 | — | 4 | 22 |
| T-cell lymphoma | D016399 | — | — | 6 | 12 | 1 | — | 5 | 21 |
| Mantle-cell lymphoma | D020522 | — | — | 7 | 14 | 3 | — | 2 | 21 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 3 | 8 | — | — | 1 | 11 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | 6 | — | — | 3 | 9 |
| Lymphoid leukemia | D007945 | — | C91 | 2 | 6 | — | — | 1 | 8 |
| T-cell lymphoma cutaneous | D016410 | — | — | 3 | 1 | — | — | 2 | 5 |
| Hematopoietic stem cell transplantation | D018380 | — | — | 1 | 3 | — | — | 2 | 5 |
| Myeloid leukemia | D007951 | — | C92 | — | 2 | — | — | 3 | 5 |
| Syndrome | D013577 | — | — | 1 | 4 | — | — | 1 | 5 |
| Melanoma | D008545 | — | — | 1 | 5 | — | — | — | 5 |
| Hematologic neoplasms | D019337 | — | — | 2 | 3 | — | — | — | 4 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 2 | — | — | 1 | 4 |
Show 63 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | 1 | 2 |
| Philadelphia chromosome | D010677 | — | — | 1 | — | — | — | — | 1 |
| Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | 1 | — | — | — | — | 1 |
| Acinar cell carcinoma | D018267 | — | — | 1 | — | — | — | — | 1 |
| Hereditary breast and ovarian cancer syndrome | D061325 | — | — | 1 | — | — | — | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Extranodal nk-t-cell lymphoma | D054391 | — | C86.0 | — | — | — | — | 2 | 2 |
| Intraocular lymphoma | D064090 | — | — | — | — | — | — | 2 | 2 |
| Lymphomatoid granulomatosis | D008230 | — | C83.8 | — | — | — | — | 2 | 2 |
| Paroxysmal hemoglobinuria | D006457 | Orphanet_447 | D59.12 | — | — | — | — | 1 | 1 |
| Hemoglobinuria | D006456 | — | R82.3 | — | — | — | — | 1 | 1 |
| Adult t-cell leukemia-lymphoma | D015459 | — | C91.5 | — | — | — | — | 1 | 1 |
| Hairy cell leukemia | D007943 | — | C91.4 | — | — | — | — | 1 | 1 |
| Large granular lymphocytic leukemia | D054066 | — | — | — | — | — | — | 1 | 1 |
| T-cell leukemia | D015458 | — | — | — | — | — | — | 1 | 1 |
| Retinoblastoma | D012175 | — | — | — | — | — | — | 1 | 1 |
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Carmustine |
| INN | carmustine |
| Description | Carmustine is a member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group. It has a role as an alkylating agent and an antineoplastic agent. It is a member of N-nitrosoureas and an organochlorine compound. |
| Classification | Small molecule |
| Drug class | antineoplastics (chloroethylamine derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=NN(CCCl)C(=O)NCCCl |
Identifiers
| PDB | — |
| CAS-ID | 154-93-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL513 |
| ChEBI ID | 3423 |
| PubChem CID | 2578 |
| DrugBank | DB00262 |
| UNII ID | U68WG3173Y (ChemIDplus, GSRS) |
Target
Agency Approved
GSR
GSR
Organism
Homo sapiens
Gene name
GSR
Gene synonyms
GLUR, GRD1
NCBI Gene ID
Protein name
glutathione reductase, mitochondrial
Protein synonyms
epididymis luminal protein 75, epididymis secretory sperm binding protein Li 122m, glutathione S-reductase, GRase
Uniprot ID
Mouse ortholog
Gsr (14782)
glutathione reductase, mitochondrial (Q8C9Z6)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,409 documents
View more details
Safety
Black-box Warning
Black-box warning for: Carmustine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,606 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use